

Original Article

Validity of Self-rating Screening Scales for the Diagnosis of Depression and Anxiety in Adult Patients With Bronchiectasis



Natalia Colomo^{a,b}, Casilda Olveira^{c,*}, Javier Hernández-Pedrosa^d, Trinidad Bergero^d, Julia Fábrega-Ruz^d, Nuria Porrás^a, María Victoria Girón^c, Luis Fernández de Rota^e, Gabriel Olveira^{a,b}

^a Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga/Universidad de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain

^b CIBER of Diabetes and Metabolic Diseases (CIBERDEM), Madrid, Spain

^c Pneumology Department, Hospital Regional Universitario de Málaga/Universidad de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain

^d Mental Health Department, Hospital Regional Universitario de Málaga/Universidad de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain

^e Pneumology Department, Hospital Costa del Sol. Marbella, Málaga, Spain

ARTICLE INFO

Article history:

Received 24 November 2019

Accepted 12 January 2020

Keywords:

Depression
Anxiety
Bronchiectasis
Infection
HADS
BDI
MINI

ABSTRACT

Background: There are no previous studies aimed at assessing the validity of the screening scales for depression and anxiety in adult patients with bronchiectasis.

Aims: To analyze the psychometric properties of Hospital Anxiety and Depression Scale (HADS), Beck Depression Inventory (BDI) and Hamilton Anxiety Scale and to evaluate the concordance for the diagnosis of depression and anxiety between these screening scales and the structured clinical interview in adult patients with bronchiectasis.

Method: Cross sectional study. 52 patients with bronchiectasis completed HADS, BDI and Hamilton Anxiety Scale; afterwards, were individually interviewed by a mental health care professional using the structured Mini International Neuropsychiatric Interview (MINI), which evaluates for depression and anxiety according to DSM-IV criteria.

Results: Based on MINI, 18 subjects (34.6%) had a diagnosis of depression and 25 (48.1%) had anxiety. Optimal cut-off values to detect depression were ≥ 9 for the HADS-D (sensitivity 0.833, specificity 0.971, AUC 0.962 [95% CI 0.918–1]), and 17 for BDI (sensitivity 0.889, specificity 0.912, AUC 0.978 [95% CI 0.945–1]). Optimal cut-off values to detect anxiety were ≥ 4 for the HADS-A (sensitivity 0.960, specificity 0.593, AUC 0.833 [95% CI 0.723–0.943]), and 17 for Hamilton Anxiety Scale (sensitivity 0.800, specificity 0.852, AUC 0.876 [95% CI 0.781–0.970]).

Conclusion: The self-rating screening scales HADS, BDI and Hamilton Anxiety Scale are reliable tools to screen for depression and anxiety in adult patients with bronchiectasis. However, the use of specific cut-off values may improve the diagnostic accuracy of the previous scales in this specific group of patients.

© 2020 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

Validez de las escalas de autoevaluación para el diagnóstico de depresión y ansiedad en pacientes adultos con bronquiectasias

RESUMEN

Contexto global: No existen estudios previos dirigidos a la evaluación de las escalas de detección de la depresión y de la ansiedad en pacientes adultos con bronquiectasias.

Objetivos: Analizar las propiedades psicométricas de la escala de ansiedad y depresión hospitalaria (HADS, por sus siglas en inglés), el inventario de depresión de Beck (BDI, por sus siglas en inglés) y la escala de ansiedad de Hamilton, y evaluar la concordancia para el diagnóstico de la depresión y la ansiedad entre estas escalas de detección y la entrevista clínica estructurada en pacientes adultos con bronquiectasias.

Método: Estudio transversal. Cincuenta y dos pacientes con bronquiectasias completaron la HADS, el BDI y la escala de ansiedad de Hamilton; posteriormente, un psiquiatra profesional de la salud mental

Palabras clave:

Depresión
Ansiedad
Bronquiectasia
Infección
HADS
BDI
MINI

* Corresponding author.

E-mail address: casi1547@separ.es (C. Olveira).

les entrevistó individualmente utilizando la entrevista estructurada denominada Minientrevista neuropsiquiátrica internacional (MINI), que evalúa la depresión y la ansiedad siguiendo los criterios del DSM-IV.

Resultados: Basándonos en la MINI, 18 sujetos (el 34,6%) fueron diagnosticados de depresión y 25 de ellos (el 48,1%) presentaba ansiedad. Los valores de corte óptimos para detectar depresión fueron ≥ 9 para la HADS-D (sensibilidad: 0,833; especificidad: 0,971; ABC: 0,962 [IC 95%: 0,918-1]) y 17 para el BDI (sensibilidad: 0,889; especificidad: 0,912; ABC: 0,978 [IC 95%: 0,945-1]). Los valores de corte óptimos para detectar ansiedad fueron ≥ 4 para la HADS-A (sensibilidad: 0,960; especificidad: 0,593; ABC: 0,833 [IC 95%: 0,723-0,943]) y 17 para la escala de ansiedad de Hamilton (sensibilidad: 0,800; especificidad: 0,852; ABC: 0,876 [IC 95%: 0,781-0,970]).

Conclusión: Las escalas de autoevaluación HADS, BDI y la escala de ansiedad de Hamilton son herramientas fiables para detectar la depresión y la ansiedad en pacientes adultos con bronquiectasias. Sin embargo, el uso de valores de corte específicos puede mejorar la precisión diagnóstica de las escalas anteriores en este grupo concreto de pacientes.

© 2020 SEPAR. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

Depression and anxiety are prevalent in the general population and represent a significant public health problem.¹⁻³ These psychiatric disorders are often under-diagnosed, occur comorbidly with chronic illnesses and are associated with worse adherence to prescribed treatments and increased health care utilization and costs.⁴⁻⁸

The gold standard for diagnosing psychiatric disorders is a structured clinical interview, such as the Structured Clinical Interview for DSM-IV.⁹ However, structured clinical interviews require administration by trained health professionals, are time-consuming and difficult to apply in routine clinical practice. Reliable, valid and easily applicable screening instruments are needed to identify patients with depression and anxiety.

The Hospital Anxiety and Depression Scale (HADS)¹⁰ and the Beck Depression Inventory (BDI)¹¹ have proved to be reliable depression screening instruments in general practice and in medical patients,^{12,13} and they have been well validated for use in the Spanish population.^{14,15} The Hamilton Anxiety Scale¹⁶ is a scale developed to measure the severity of anxiety symptoms, and it has been validated for use in the Spanish population.¹⁷

Bronchiectasis is the end result of several different diseases, managed in similar ways, but which lead to pulmonary infections, loss of lung function and worsening of health related quality of life.^{18,19} Recent studies have shown that patients with bronchiectasis have a higher prevalence of symptoms of depression (between 20 and 30%) and anxiety (around 40%) than healthy subjects.²⁰⁻²³ However, these studies used screening scales such as HADS and BDI, and not a psychological evaluation performed by a mental health professional, to evaluate the presence of symptoms of depression and anxiety.

There are no previous studies aimed at assessing the validity of the screening scales for depression and anxiety in adult patients with bronchiectasis. Accordingly, the purpose of the present study was to analyze the psychometric properties of the self-rating screening scales for depression and anxiety; and to evaluate the concordance for the diagnosis of symptoms of depression and anxiety between these screening scales and the structured clinical interview for DSM-IV in patients with bronchiectasis.

Method

Patients

This is a cross sectional study that included patients with a diagnosis of bronchiectasis who were monitored periodically (every

2–3 months) in the adult bronchiectasis/cystic fibrosis unit at the Hospital Regional Universitario de Málaga (Málaga, Spain) between May 2012 and May 2013.

Inclusion criteria: patients aged 16 and older with bronchiectasis of any etiology (including cystic fibrosis) who attended the adult bronchiectasis/cystic fibrosis unit for routine review. If at this time they had a respiratory exacerbation or a recent hospital admission, their inclusion was postponed at least 30 days until completion of treatment of the acute process. In all cases bronchiectasis was diagnosed by high-resolution computerized tomography of the chest with the use of a 1–1.5 mm window for every 10 mm with acquisition times of 1 s during full inspiration, following the criteria of Naidich et al.²⁴ All patients underwent a full etiological study following the diagnostic algorithm of bronchiectasis of the Sociedad Española de Neumología y Cirugía Torácica (SEPAR).¹⁹ **Exclusion criteria:** transplant waiting list, problems understanding the questionnaires, absence of written informed consent.

The Research Ethics Committee of the Hospital Regional de Málaga approved the study. All participants gave written informed consent.

Measurements

The day of the appointment at the bronchiectasis/cystic fibrosis unit, patients who met inclusion criteria and none of the exclusion criteria were invited to participate. Written informed consent was obtained from each participant before inclusion.

Sociodemographic data were collected, including age, sex, marital/partner status, employment status and educational level.

A full clinical history, from diagnosis through to study participation, was recorded in a regional database. During each visit, clinical variables were collected prospectively, including body mass index (BMI), spirometry and sputum samples for microbiologic analysis. Pulmonary exacerbations were assessed prospectively using the SEPAR criteria.¹⁹ Forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) were expressed in absolute terms (ml) and as a percentage using a reference population.²⁵ The number of exacerbations and hospital admissions in the year prior to the evaluation were also utilized in the analyses. Anxiolytic and antidepressant intake was also recorded.

The day of the inclusion in the study, patients completed the self-reported HADS questionnaire, the BDI, the Hamilton Anxiety Scale and the QOL-B questionnaire (in case of non cystic fibrosis patients) and CFQ-R (in case of cystic fibrosis patients). Afterwards, each participant received a specific appointment with a mental health care professional to conduct a structured clinical interview.

The HADS questionnaire¹⁰ comprises two sub-scales, each one ranges from 0 to 21 points; one assesses the symptoms of depression (HADS-D), and the other one the symptoms of anxiety (HADS-A). It was validated in Spanish, including patients with respiratory pathology (chronic obstructive pulmonary disease – COPD).²⁶ The following severity cut-off scores for anxiety and depression have been recommended by the authors of the measure: In each sub-scale, a score below 7 is considered normal range, between 8 and 10 means probable presence of depression or anxiety respectively, and more than 11 suggests the presence of depression or anxiety respectively. These cut-off points have been previously used in patients with Cystic Fibrosis and bronchiectasis.²⁷

The BDI¹¹ is a 21-item-self report-multiple choice inventory. BDI items are rated on a 4-point scale ranging from 0 to 3 based on severity of each item; the maximum total score is 63. The following severity cut-off scores have been recommended: below 9 is considered no depression, between 10 and 18 probable mild depression, between 19 and 29 probable moderate depression, and more than 30 probable severe depression. However, other cut-off points have also been proposed in patients with respiratory diseases such as COPD.²⁸

The Hamilton Anxiety Scale¹⁶ consists of 14 items, each defined by a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0–56, where <17 indicates mild severity, 17–24 mild to moderate severity and 25–30 moderate to severe. These cut-off points have been used in patients with COPD.²⁹

The structured clinical interview: patients were individually interviewed by a mental health care professional (who was blinded to the scores obtained in the self-reported questionnaires) using the Spanish version 5.0.0 of the structured Mini International Neuropsychiatric Interview (MINI).^{30,31} The MINI evaluates for depression and anxiety according to the DSM-IV criteria.⁹ The outcome in the MINI was considered the gold standard.

QOL-B-Spain: is a disease-specific questionnaire for patients with bronchiectasis in Spanish. It is a self-report measure consisting of 37 questions divided into 8 domains, and takes about 10 min to complete. The scores are standardized across 8 scales, ranging from 0 to 100, with higher scores indicating better health-related quality of life.³²

CFQR 14+ (Spain): is a disease-specific questionnaire for patients with cystic fibrosis in Spanish. It is a self-report measure consisting of 50 questions and takes about 10–15 min to complete. The scores are standardized across 12 scales, ranging from 0 to 100, with higher scores indicating better health-related quality of life.^{14,33} QOLB and CFQ-R share 8 scales that are the ones analyzed in this work: Physical functioning, Role functioning Vitality, Emotional functioning, Social functioning, Treatment burden, Health perceptions, Respiratory symptoms.

Statistical analysis

We present psychometric properties of the HADS-D, HADS-A, BDI and Hamilton Anxiety Scale at various optimal cut-off values and at traditionally accepted cut-off values. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated. Agreement between the screening scales and the diagnoses obtained by the MINI was measured using kappa coefficient and by calculating the area under the receiver operating (ROC) curve (AUC). Maximal discrimination between those with or without a DSM-IV diagnosis was reached at the highest sum of sensitivity and specificity that is termed the Youden

index.³⁴ The normality of distributions was verified using the Kolmogorov–Smirnov test. Quantitative variables were compared using *t* tests or the Mann–Whitney test. Additionally, the Spearman correlation coefficient was employed in order to assess correlations between the screening scales of depression and anxiety, clinical variables and QOL-B and CFQ-R dimensions. To test the statistical significance of the difference between the areas under 2 dependent ROC curves we used the method of DeLong. Confidence levels of 95% were considered in two tail hypothesis tests.

Results

A total of 52 subjects were included (71.2% women, mean age of 44 years old). Thirty subjects (57.7%) had a diagnosis of non-cystic fibrosis bronchiectasis, and 22 (42.3%) had a diagnosis of cystic fibrosis. Table 1 describes the sociodemographic and clinical characteristics of the study participants.

The results of the MINI based on the DSM-IV criteria showed that 18 subjects (34.6%) had a diagnosis of depression, and 25 subjects (48.1%) had a diagnosis of anxiety.

Table 2 summarizes the psychometric properties of the HADS-D subscale and the BDI compared with the MINI for the diagnosis of depression. Optimal cut-off values were ≥ 9 for the HADS-D (sensitivity 0.833, specificity 0.971), and 17 for BDI (sensitivity 0.889, specificity 0.912). Fig. 1a and b shows the ROC curves for the HADS-D and the BDI, respectively. The AUC was 0.962 (95% CI 0.918–1) for the HADS-D, and 0.978 (95% CI 0.945–1) for the BDI. Difference between areas was 0.0155 (95% CI –0.0378 to 0.0688); $p = 0.5681$.

Table 3 summarizes the psychometric properties of the HADS-A subscale and the Hamilton Anxiety Scale compared with the MINI for the diagnosis of anxiety. Optimal cut-off values were ≥ 4 for the HADS-A (sensitivity 0.960, specificity 0.593) and 17 for the Hamilton Anxiety Scale (sensitivity 0.800, specificity 0.852). Fig. 1c and d shows the ROC curves for the HADS-A and the Hamilton Anxiety Scale, respectively. The AUC was 0.833 (95% CI 0.723–0.943) for the HADS-A, and 0.876 (95% CI 0.781–0.970) for the Hamilton Anxiety Scale. Difference between areas was 0.0422 (95% CI –0.0694 to 0.154); $p = 0.4585$.

We found significant correlations between the score of the scales HADS-D, HADS-A, BDI and the Hamilton Anxiety Scale with each other and with all the dimensions of the QOL-B and CFQ-R, except for treatment burden. We do not observe significant correlations of the scores of the scales with clinical variables such as BMI, age, FEV1%, or exacerbations rate (Table 4). Patients with *Pseudomonas aeruginosa* or any chronic bronchial infection did not have significantly different scores from any of the self-rated screening scale for depression and anxiety studied relative to those not colonized (data not shown).

Discussion

Anxiety and depression are commonly reported in patients with bronchiectasis, therefore in this group of patients it is especially important to screen for the presence of symptoms of these psychiatric disorders in the Bronchiectasis Units, and refer the right patients to a mental health team for treatment. The prevalence varies among different studies, which depends on the method of diagnosis. In previous studies performed in this group of patients using screening scales to diagnose depression and anxiety, the prevalence of depression symptoms ranges between 20 and 34%, and the prevalence of anxiety between 38 and 55%.^{20–23} In the present study, the MINI revealed a prevalence of depression of 34.6% and anxiety of 48.1%. To our knowledge this is the first study in patients with bronchiectasis in which a structured clinical interview was performed.

Table 1
Sociodemographic and clinical characteristics of the study participants.

Study variables	N (%) or mean \pm SD ^a
Age (years)	44.2 \pm 16.2
Sex	
Male	15 (28.8)
Female	37 (71.2)
Marital status	
Single	15 (28.8)
Married or cohabitant	33 (63.5)
Divorced or separated	1 (1.9)
Widowed	2 (3.8)
Employment status	
Able to work	30 (57.7)
Unemployed	10 (19.2)
Retired	12 (23.1)
Educational level	
No education	5 (9.6)
Primary school	19 (36.5)
Secondary school	18 (34.6)
College	10 (19.2)
Drug use	
Anxiolytics	12 (23.1)
Antidepressants	5 (9.6)
Respiratory disease	
Bronchiectasis non-cystic fibrosis	30 (57.7)
Cystic fibrosis	22 (42.3)
FEV1	
MI	1971 \pm 932
%	65.8 \pm 27.9
Respiratory exacerbations in the last 12 months (n)	
Total	2.02 \pm 1.56
Mild	1.78 \pm 1.44
Severe	0.26 \pm 0.53
Colonization of the respiratory tract (n, %)	
Any bacteria	39 (79.6)
<i>Haemophilus influenzae</i>	25 (49.0)
<i>Pseudomonas aeruginosa</i>	36 (70.6)
<i>Staphylococcus aureus</i>	22 (43.1)
Methicillin-resistant <i>Staphylococcus aureus</i>	1 (2.0)
Body mass index (kg/m ²)	24.5 \pm 5.7
Screening scales	
HADS-depression score	5.8 \pm 4.8
HADS-anxiety score	7.9 \pm 5.3
BDI score	12.1 \pm 11.3
Hamilton scale score	17.1 \pm 11.6
MINI	
Depression	18 (34.6)
Anxiety	25 (48.1)
Quality of life dimensions	
Physical	56.8 \pm 34.0
Role	70.9 \pm 27.7
Vitality	54.6 \pm 27.9
Emotion	69.1 \pm 28.1
Social	72.2 \pm 25.5
Treatment	66.1 \pm 22.6
Health	46.3 \pm 27.4
Respiratory	73.4 \pm 22.5

FEV1: forced expiratory volume in the first second; HADS: Hospital Anxiety and Depression Scale.

^a Categorical variables are n (%) and continuous variables are mean \pm standard deviation.

The optimal cut-off values of the screening scales in patients with bronchiectasis might differ from the ones traditionally accepted, as have been reported previously in other diseases. Optimal cut-off values for the diagnosis of depression using HADS-D ranges between 7 in patients on hemodialysis³⁵ and in patients

with obstructive pulmonary disease,²⁸ and 8 in patients with coronary artery disease¹³ and in patients with systemic lupus erythematosus.³⁶ For the BDI, an optimal cut-off point of 14 was reported in a study with patients on hemodialysis,³⁵ and an optimal cut-off point of 13 was found in patients with obstructive pulmonary disease.²⁸ For the anxiety screening scales, the optimal cut-off point for HADS-A was 6 in patients with systemic lupus erythematosus³⁶ and in patients on hemodialysis,³⁵ 8 in patients with coronary artery disease,¹³ 9 in patients with obstructive pulmonary disease.²⁸

However, we did not find any studies that assess the psychometric properties of the screening scales to detect depression and anxiety in patients with bronchiectasis. We believe it to be of interest because of the high prevalence of these psychiatric disorders in this specific group of patients, and the negative consequences of the under-diagnosis and under-treatment of these psychiatric symptoms on the quality of life and disease severity.^{20–22}

Therefore, in the present study we assessed the optimal cut-off points of the screening scales (HADS-D, BDI, HADS-A and Hamilton Anxiety Scale) to determine the most sensitive and specific value to detect depression and anxiety of each scale in this specific group of patients. To detect depression, we found that the optimal cut-off value for the HADS-D was 9, and for the BDI it was 14. These cut-off points for both scales are close to, but are not the standard recommendation.^{10,11} Additionally, both HADS-D and BDI have a high and similar AUC to detect depression and may be used indistinctly as a tool for screening depression in patients with bronchiectasis. To detect anxiety, our results showed that the optimal cut-off value for HADS-A was 4, and for the Hamilton Anxiety Scale was 17. In this case, we found that the standard cut-off point recommendation for HADS-A has a low sensitivity in patients with bronchiectasis, thus we propose using 4 as the cut-off point in order to improve the performance of the HADS-A in this group of patients. For the Hamilton Anxiety Scale, we suggest using 17 as a cut-off point to detect anxiety. HADS-A and the Hamilton Anxiety Scale have a good and similar AUC to detect anxiety.

The scores of the three scales evaluated (HADS, BDI and Hamilton) have presented significant negative correlations (higher scores, worse quality of life) with the 8 dimensions of the patients reported outcome QOL-B and CFQ-R evaluated, except for treatment burden, being especially high in the emotional functioning dimension. On the contrary, we do not observe significant associations of HADS, BDI or Hamilton scores, with individual important components such as BMI, age, *P. aeruginosa* or any chronic bronchial infection, FEV1%, or exacerbations rate. These results are similar to those previously found by our group where symptoms of depression and anxiety were significant predictors of health-related quality of life in patients with bronchiectasis, independently of respiratory involvement, age or other variables. These results reinforce the importance of assessing symptoms of depression/anxiety in bronchiectasis because it adds new information on the impact of the disease on the patient. So the current multidimensional scoring systems like such as the Bronchiectasis Severity Index (BSI), FACED, and e-FACED^{37–39} developed in bronchiectasis are useful to assess the clinical severity and prognosis of the disease, but they do not include other important dimensions such as the impact of bronchiectasis upon the patient.^{40,41}

The strength of the study is that is the first paper on this topic in patients with bronchiectasis and includes the evaluation of associations of screening test with clinical and quality of life variables. The limitation is that we have included patients with and without CF (and probably the characteristics of these two groups could be different). In any case, a specific test for CF such as CFQ-R and non-bronchiectasis for QOL-B has been used for the evaluation of quality

Table 2
Psychometric properties at optimal cut-off values and traditionally accepted cut-off values of the depression screening scales.

Cut-off score	Sensitivity	Specificity	PPV	NPV	Youden index	Kappa	AUC
<i>HADS-D</i>							0.962 (0.918–1)
6	0.944	0.765	0.680	0.963	0.709	0.650 (<0.001)	
7	0.833	0.882	0.789	0.909	0.715	0.706 (<0.001)	
8	0.833	0.912	0.833	0.912	0.745	0.745 (<0.001)	
9	0.833	0.971	0.937	0.917	0.804	0.826 (<0.001)	
10	0.722	0.971	0.928	0.868	0.693	0.731 (<0.001)	
11	0.667	1	0.100	0.850	0.667	0.723 (<0.001)	
<i>BDI</i>							0.978 (0.945–1)
10	0.944	0.794	0.708	0.964	0.738	0.685 (<0.001)	
15	0.889	0.941	0.889	0.941	0.830	0.830 (<0.001)	
17	0.889	0.917	0.941	0.942	0.860	0.871 (<0.001)	
18	0.833	0.971	0.937	0.917	0.804	0.826 (<0.001)	

AUC: area under the curve; BDI: Beck Depression Inventory; HADS-D: Hospital Anxiety and Depression Scale – Depression subscale; NPV: negative predictive value; PPV: positive predictive value. Bold: optimal cut-off values.

HADS-D: AUC 0.962. CI 95% (0.918–1); $p < 0.0001$.

BDI: AUC 0.978. CI 95% (0.945–1); $p < 0.0001$.




Fig. 1. ROC curves of the self-rating screening scales compared with MINI. (a) and (b) show the ROC curves for the HADS-D and the BDI, respectively, compared with the MINI for the diagnosis of depression. (c) and (d) show the ROC curves for the HADS-A and the Hamilton Anxiety Scale, respectively, compared with the MINI for the diagnosis of anxiety.

of life, since both questionnaires share the same 8 dimensions analyzed in this study.

In conclusion, the self-rating screening scales HADS, BDI and Hamilton Anxiety Scale are reliable tools to screen for depression

and anxiety in adult patients with bronchiectasis. However, our results suggest that the use of specific cut-off values may improve the diagnostic accuracy of the previous scales in patients with bronchiectasis.

Table 3
Psychometric properties at optimal cut-off values and traditionally accepted cut-off values of the anxiety screening scales.

Score	Sensitivity	Specificity	PPV	NPV	Youden index	Kappa	AUC
							0.833 (0.723–0.943)
HADS-A							
3	0.960	0.370	0.585	0.909	0.330	0.323 (0.004)	
4	0.960	0.593	0.686	0.941	0.553	0.545 (<0.001)	
6	0.880	0.667	0.710	0.857	0.547	0.542 (<0.001)	
7	0.800	0.704	0.714	0.792	0.504	0.501 (<0.001)	
11	0.560	0.815	0.737	0.667	0.375	0.378 (0.005)	
							0.876 (0.781–0.970)
Hamilton							
6	0.960	0.333	0.500	0.900	0.293	0.286 (0.007)	
15	0.840	0.704	0.724	0.826	0.544	0.541 (<0.001)	
16	0.800	0.778	0.769	0.808	0.578	0.577 (<0.001)	
17	0.800	0.852	0.833	0.821	0.652	0.653 (<0.001)	
18	0.760	0.852	0.826	0.793	0.612	0.614 (<0.001)	

AUC: area under the curve; HADS-A: Hospital Anxiety and Depression Scale – Anxiety subscale; NPV: negative predictive value; PPV: positive predictive value.

Bold: optimal cut-off values in bold.

HADS-A: AUC 0.833. CI 95% (0.723–0.943); $p < 0.0001$.

Hamilton: AUC 0.876. CI 95% (0.781–0.970); $p < 0.0001$.

Table 4
Correlations (Spearman correlation coefficient) between the screening scales of depression and anxiety, clinical variables and quality of life score.

Correlation coefficient	HADS-A	HADS-D	BDI	Hamilton
HADS-A	1.000	.763***	.782***	.702***
HADS-D	.763***	1.000	.838***	.772***
BDI	.782***	.838***	1.000	.810***
Hamilton	.702***	.772***	.810***	1.000
BMI	.000	.103	.089	-.014
Age	.061	.225	.113	.212
FEV1%	-.026	-.149	.002	-.044
Exacerbation	.081	-.039	-.060	-.101
QOL Physical	-.559***	-.633***	-.520***	-.511***
QOL Role	-.588***	-.673***	-.676***	-.521***
QOL Vitality	-.748***	-.711***	-.767***	-.694***
QOL Emotion	-.748***	-.711***	-.767***	-.694***
QOL Social	-.488***	-.465**	-.437*	-.315*
QOL Treatment	-.244	-.267	-.295	-.156
QOL Health	-.685***	-.609***	-.701***	-.589***
QOL Respiratory	-.445**	-.482**	-.536***	-.471**

BDI: Beck Depression Inventory; HADS: Hospital Anxiety and Depression Scale; HADS-A: Hospital Anxiety and Depression Scale – Anxiety subscale; HADS-D: Hospital Anxiety and Depression Scale – Depression subscale; QOL: quality of life score.

Spearman correlation coefficient.

* $p < 0.05$.

** $p < 0.01$.

*** $p < 0.0001$.

Authors' contributions

G.O. and C.O. substantially contributed to the conception and design of the study, acquisition, analysis, and interpretation of the data; statistical analysis; and drafting of the manuscript. N.C. contributed to the acquisition, analysis, and interpretation of the data; statistical analysis; revised the article for important intellectual content and drafting of the manuscript; J.H.-P., T.B., J.F.-R., N.P. M.V.G., and L.F.D.R. contributed to the data acquisition and critical review of the manuscript.

G.O. is the guarantor of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Conflict of interests

The authors declare no conflict of interest.

Acknowledgements

We would like to thank every patient has participated in this study.

References

- Roy-Byrne PP, Davidson KW, Kessler RC, Asmundson GJG, Goodwin RD, Kubzansky L, et al. Anxiety disorders and comorbid medical illness. *Gen Hosp Psychiatry*. 2008;30:208–25.
- U.S. Preventive Services Task Force. Screening for depression in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2009;151:784.
- Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H-U. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. *Int J Methods Psychiatr Res*. 2012;21:169–84.
- Cruz I, Marciel KK, Quittner AL, Schechter MS. Anxiety and depression in cystic fibrosis. *Semin Respir Crit Care Med*. 2009;30:569–78.
- Holvast F, Wouters H, Hek K, Schellevis F, Oude Voshaar R, van Dijk L, et al. Non-adherence to cardiovascular drugs in older patients with depression: a population-based cohort study. *Int J Cardiol*. 2019;274:366–71.
- DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. *Arch Intern Med*. 2000;160:2101–7.
- Puyat JH, Kazanjian A, Wong H, Goldner E. Comorbid chronic general health conditions and depression care: a population-based analysis. *Psychiatr Serv*. 2017;68:907–15.
- Katon W, Lin EHB, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. *Gen Hosp Psychiatry*. 2007;29:147–55.
- Association AP. Diagnostic and statistical manual of mental disorders; 2000. Washington.
- Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*. 1983;67:361–70.

11. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. *Arch Gen Psychiatry*. 1961;4:561–71.
12. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. *J Psychosom Res*. 2002;52:69–77.
13. Bunevicius A, Staniute M, Brozaitiene J, Bunevicius R. Diagnostic accuracy of self-rating scales for screening of depression in coronary artery disease patients. *J Psychosom Res*. 2012;72:22–5.
14. Herrero MJ, Blanch J, Peri JM, De Pablo J, Pintor L, Bulbena A. A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population. *Gen Hosp Psychiatry*. 2003;25:277–83.
15. Vázquez C, Sanz J. Fiabilidad y validez de la versión española del Inventario para la Depresión de Beck de 1978 en pacientes con trastornos psicológicos. *Clín Salud*. 1999;10:59–81.
16. Hamilton M. The assessment of anxiety states by rating. *Br J Med Psychol*. 1959;32:50–5. <http://dx.doi.org/10.1111/j.2044-8341.1959.tb00467.x> [Internet].
17. Lobo A, Chamorro L, Luque A, Dal-Ré R, Badia X, Baró E, et al. [Validation of the Spanish versions of the Montgomery-Asberg depression and Hamilton anxiety rating scales]. *Med Clin (Barc)*. 2002;118:493–9.
18. Martínez-García MA, Villa C, Dobarganes Y, Girón R, Oliveira C, Maíz L, et al. RIBRON: el registro español informatizado de bronquiectasias. Caracterización de los primeros 1,912 pacientes. *Arch Bronconeumol*. 2020 [in press].
19. Martínez-García MÁ, Maíz L, Oliveira C, Girón RM, de la Rosa D, Blanco M, et al. Spanish guidelines on the evaluation and diagnosis of bronchiectasis in adults. *Arch Bronconeumol (Engl Ed)*. 2018;54:79–87.
20. Gao Y-H, Guan W-J, Zhu Y-N, Chen R-C, Zhang G-J. Anxiety and depression in adult outpatients with bronchiectasis: associations with disease severity and health-related quality of life. *Clin Respir J*. 2018;12:1485–94.
21. Özgün Niksarlioglu EY, Özkan G, Günlüoğlu G, Uysal MA, Gül S, Kilic L, et al. Factors related to depression and anxiety in adults with bronchiectasis. *Neuropsychiatr Dis Treat*. 2016;12:3005–10.
22. Oliveira C, Oliveira G, Gaspar I, Dorado A, Cruz I, Soriquer F, et al. Depression and anxiety symptoms in bronchiectasis: associations with health-related quality of life. *Qual Life Res*. 2013;22:597–605.
23. Girón Moreno RM, Fernandes Vasconcelos G, Cisneros C, Gómez-Punter RM, Segrelles Calvo G, Ancochea J. Presence of anxiety and depression in patients with bronchiectasis unrelated to cystic fibrosis. *Arch Bronconeumol (Engl Ed)*. 2013;49:415–20.
24. Naidich DP, McCauley DI, Khouri NF, Stitik FP, Siegelman SS. Computed tomography of bronchiectasis. *J Comput Assist Tomogr*. 1982;6:437–44.
25. Roca J, Sanchis J, Agusti-Vidal A, Segarra F, Navajas D, Rodríguez-Roisin R, et al. Spirometric reference values from a Mediterranean population. *Bull Eur Physiopathol Respir*. 1986;22:217–24.
26. Quintana JM, Padierna A, Esteban C, Arostegui I, Bilbao A, Ruiz I. Evaluation of the psychometric characteristics of the Spanish version of the Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand*. 2003;107:216–21.
27. Oliveira C, Oliveira G, Espildora F, Girón R-M, Vendrell M, Dorado A, et al. Mediterranean diet is associated on symptoms of depression and anxiety in patients with bronchiectasis. *Gen Hosp Psychiatry*. 2014;36:277–83.
28. Phan T, Carter O, Adams C, Waterer G, Chung LP, Hawkins M, et al. Discriminant validity of the Hospital Anxiety and Depression Scale Beck Depression Inventory (II) and Beck Anxiety Inventory to confirmed clinical diagnosis of depression and anxiety in patients with chronic obstructive pulmonary disease. *Chronic Respir Dis*. 2016;13:220–8.
29. Obradovic LMN, Pesut DP, Maric D, Maskovic J, Maric NP, Milikic MM. Symptoms of anxiety and depression in patients with chronic obstructive pulmonary disease. *Pneumologia*. 2012;61:92–6.
30. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry*. 1998;59 Suppl.:22–33, quiz 34–57.
31. Ferrando L, Bobes J, Gibert J. MINI, international neuropsychiatric interview. Spanish version 5.0.0. DSM-IV; 2000. Madrid.
32. Oliveira C, Oliveira G, Espildora F, Giron RM, Muñoz G, Quittner AL, et al. Validation of a Quality of Life Questionnaire for Bronchiectasis: psychometric analyses of the Spanish QOL-B-V3.0. *Qual Life Res*. 2014;23:1279–92.
33. Oliveira C, Oliveira C, Gaspar I, Cruz I, Dorado A, Pérez-Ruiz E, et al. Validación de la versión española del cuestionario revisado de calidad de vida para fibrosis quística en adolescentes y adultos (CFQR 14+ Spain). *Arch Bronconeumol*. 2010;46:165–75.
34. Youden WJ. Index for rating diagnostic tests. *Cancer*. 1950;3:32–5.
35. Preljevic VT, Østhus TBH, Sandvik L, Opjordsmoen S, Nordhus IH, Os I, et al. Screening for anxiety and depression in dialysis patients: comparison of the Hospital Anxiety and Depression Scale and the Beck Depression Inventory. *J Psychosom Res*. 2012;73:139–44.
36. Kwan A, Marzouk S, Ghanean H, Kishwar A, Anderson N, Bonilla D, et al. Assessment of the psychometric properties of patient-reported outcomes of depression and anxiety in systemic lupus erythematosus. *Semin Arthritis Rheum*. 2019;49:260–6.
37. Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index. An international derivation and validation study. *Am J Respir Crit Care Med*. 2014;189:576–85.
38. Martínez-García MA, de Gracia J, Vendrell Relat M, Giron R-M, Maíz Carro L, de la Rosa Carrillo D, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. *Eur Respir J*. 2014;43:1357–67.
39. Martínez-García MA, Athanazio RA, Girón R, Maíz-Carro L, de la Rosa D, Oliveira C, et al. Predicting high risk of exacerbations in bronchiectasis: the E-FACED score. *Int J Chron Obstruct Pulmon Dis*. 2017;12:275–84.
40. Martínez-García MA, Aksamit TR, Agusti A. Clinical fingerprinting: a way to address the complexity and heterogeneity of bronchiectasis in practice. *Am J Respir Crit Care Med*. 2020;201:14–9.
41. De la Rosa Carrillo D, Oliveira C, García-Clemente M, Girón-Moreno R, Nieto-Royo R, Navarro-Rolon A, et al. COPD assessment test in bronchiectasis: minimum clinically important difference and psychometric validation. *Chest*. 2019.